Hypoglycemia Is BAD

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Hypoglycemia The Scope of the Problem

Hypoglycemia Session at ADA 2018

The Many Faces of Hypoglycemia Impact on Patient Health and Well-Being

Impact of Hypoglycemia on the Brain Insights From Structural and Functional Neuroimaging

Brain Structural Changes Seen in People With T1D and IAH

Hypoglycemia Unawareness and the Brain

Impact of Hypoglycemia on Patient-Reported Outcomes and Quality of Life

Hypoglycemia and CV Mortality

The Link Between Hypoglycemia and Arrhythmias

Hypoglycemia Session at ADA 2018 (cont)

Hypoglycemia—Who Is at Risk and Who Is Most Likely to Be Harmed?

Leveraging Technology to Detect, Prevent, and Treat Hypoglycemia

Hypoglycemia Session at ADA 2018 (cont)

New Definition of Hypoglycemia—Why Does It Matter?

Glucose Values Are Actionable Data

Economic Impact of Severe Hypoglycemia

SWITCH 2 Trial Design

Key Results from SWITCH 2 16-Week Maintenance Period

New Data From ADA 2018—SWITCH 2 Hypoglycemia by Age Group, 16-Week Maintenance Period

DEVOTE CV Outcomes Trial With Degludec

Key Results From DEVOTE

New Data From ADA 2018—DEVOTE CV Safety and Risk for Severe Hypoglycemia in Older Adults

BRIGHT Trial Glargine U300 vs Degludec U100

Incidence of Hypoglycemia Similar Between Glargine U300 and Degludec U100

Interpreting the BRIGHT, DEVOTE, and SWITCH Trials

Closing Comments

Abbreviations

Abbreviations (cont)